65 results on '"Zhao, Qinjian"'
Search Results
2. Pairwise antibody footprinting using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization
- Author
-
Towne, Victoria, Zhao, Qinjian, Brown, Martha, and Finnefrock, Adam C.
- Subjects
- *
IMMUNOGLOBULINS , *SURFACE plasmon resonance , *PAPILLOMAVIRUSES , *IMMOBILIZED antibodies , *EPITOPES , *MONOCLONAL antibodies - Abstract
Abstract: This paper describes an approach to surface plasmon resonance (SPR) based epitope mapping, also referred to as pairwise antibody footprinting, involving the direct immobilization of an antigen-specific primary mAb to the surface of an SPR interface. This technique offers a more straightforward approach than indirect capture (e.g., via rabbit anti-mouse Fc) as it does not require additional steps to block the unoccupied immobilized anti-Fc to prevent non-specific antibody binding. This is also an alternative to the direct immobilization of an antigen of interest, which may cause conformational changes in the antigen or epitope degradation upon chemical immobilization, particularly in successive regeneration cycles. It is particularly suitable for highly multivalent targets such as virus-like particles (VLPs). Using this technique, we assessed a panel of eight monoclonal antibodies against HPV (human papilloma virus) L1 protein VLPs expressed by Saccharomyces cerevisiae. In the antibody epitope screening studies, HPV16 L1-directed conformational mAbs were clearly distinguished from the linear mAbs and consistent with known epitope information. Additional studies using a linear mAb and a conformational mAb demonstrate the practical application of this technique for characterizing the result of process changes and the consistency of recombinant HPV16 VLPs. The method is readily extensible to other VLPs and VLP-based vaccines. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
3. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.
- Author
-
Zhao, Qinjian, Zhang, Jun, Wu, Ting, Li, Shao-Wei, Ng, Mun-Hon, Xia, Ning-Shao, and Shih, James Wai-Kuo
- Abstract
There is emerging evidence for an under-recognized hepatitis E virus (HEV) as a human pathogen. Among different reasons for this neglect are the unsatisfactory performance and under-utilization of commercial HEV diagnostic kits; for instance, the number of anti-HEV IgM kits marketed in China is about one-fifth of that of hepatitis A kits. Over the last two decades, substantial progress has been achieved in furthering our knowledge on the HEV-specific immune responses, antigenic features of HEV virions, and development of serological assays and more recently prophylactic vaccines. This review will focus on presenting the evidence of the importance of HEV infection for certain cohorts such as pregnant women, the key antigenic determinants of the virus, and immunogenicity and clinical efficacy conferred by a newly developed prophylactic vaccine. Robust immunogenicity, greater than 195-fold and approximately 50-fold increase of anti-HEV IgG level in seronegative and seropositive vaccinees, respectively, as well as impressive clinical efficacy of this vaccine was demonstrated. The protection rate against the hepatitis E disease and the virus infection was shown to be 100% (95% CI 75-100) and 78% (95% CI 66-86), respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.
- Author
-
Zhao, Qinjian, Zhang, Jun, Wu, Ting, Li, Shao-Wei, Ng, Mun-Hon, Xia, Ning-Shao, and Shih, James
- Subjects
- *
HEPATITIS E , *VIRAL antigens , *VIRAL vaccines , *DRUG efficacy , *IMMUNE response , *IMMUNOGLOBULIN G , *THERAPEUTICS - Abstract
There is emerging evidence for an under-recognized hepatitis E virus (HEV) as a human pathogen. Among different reasons for this neglect are the unsatisfactory performance and under-utilization of commercial HEV diagnostic kits; for instance, the number of anti-HEV IgM kits marketed in China is about one-fifth of that of hepatitis A kits. Over the last two decades, substantial progress has been achieved in furthering our knowledge on the HEV-specific immune responses, antigenic features of HEV virions, and development of serological assays and more recently prophylactic vaccines. This review will focus on presenting the evidence of the importance of HEV infection for certain cohorts such as pregnant women, the key antigenic determinants of the virus, and immunogenicity and clinical efficacy conferred by a newly developed prophylactic vaccine. Robust immunogenicity, greater than 195-fold and approximately 50-fold increase of anti-HEV IgG level in seronegative and seropositive vaccinees, respectively, as well as impressive clinical efficacy of this vaccine was demonstrated. The protection rate against the hepatitis E disease and the virus infection was shown to be 100 % (95 % CI 75-100) and 78 % (95 % CI 66-86), respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization
- Author
-
Zhao, Qinjian, Towne, Victoria, Brown, Martha, Wang, Yang, Abraham, Dicky, Oswald, C. Brent, Gimenez, Juan A., Washabaugh, Michael W., Kennedy, Ronald, and Sitrin, Robert D.
- Subjects
- *
OXIDATION-reduction reaction , *IMMUNOCHEMISTRY , *HEPATITIS B treatment , *MONOCLONAL antibodies , *CONFORMATIONAL analysis , *ENZYME-linked immunosorbent assay , *VIRAL vaccines - Abstract
Abstract: Recombinant Hepatitis B surface antigen virus-like particles (VLPs) produced in yeast undergo spontaneous maturation during the vaccine production process, and the biophysical characteristics of the particles with respect to maturation were described in Zhao et al. (2006) . Here we report additional biochemical and immunochemical characterization by various techniques, including the use of a panel of monoclonal antibodies (mAbs) that differ in their selectivity and conformation-sensitivity, for probing surface epitope structures. Crosslinking via interchain disulfide formation and binding of conformational specific antibodies in the mature particles were shown to be progressively enhanced. We show that redox-mediated VLP maturation is superior to heat-induced maturation in terms of generating VLPs which exhibit more complete crosslinking (>95%) and 2- to 3-fold higher antigenicity as defined by conformational antibodies. Therefore, the resulting VLPs from redox treatment resemble more closely their plasma-derived counterparts. The value of using multiple mAbs for probing surface epitopes was clearly demonstrated as different mAbs showed different degrees of sensitivity to the structural changes during HBsAg VLP maturation. The rapid, label-free technology of surface plasmon resonance performed at a single antigen concentration was shown to correlate well with a sandwich ELISA using parallel line analysis, currently implemented for product release and stability testing of RECOMBIVAX HB®. Surface plasmon resonance offers both convenience and flexibility; multiple mAbs can be tested one at a time in the same set of experiments, providing a means to assess changes to individual epitopes. Taken together, these quantitative analytical tools enable more rapid, in-depth, and comprehensive process monitoring, process optimization, and assessment of product consistency and stability. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
6. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment
- Author
-
Zhao, Qinjian, Wang, Yang, Abraham, Dicky, Towne, Victoria, Kennedy, Ronald, and Sitrin, Robert D.
- Subjects
- *
HEPATITIS B virus , *CELL surface antigens , *EPITOPES , *HEAT treatment , *SURFACE plasmon resonance , *OXIDATION-reduction reaction , *MOLECULAR structure , *MONOCLONAL antibodies - Abstract
Abstract: The Hepatitis B virus major surface antigen (HBsAg) is a cysteine-rich, membrane-bound protein which self-assembles into 22-nm spherical virus-like particles (VLPs). While this VLP based human vaccine has been demonstrated to be safe and efficacious since 1986, the structural and exact molecular basis for its antigenic determinants has not been elucidated. Maturation of the yeast-derived purified VLPs was characterized for the changes in 37 their biophysical properties . Using rapid and label-free surface plasmon resonance technique with a neutralizing monoclonal antibody – A1.2, the epitope evolution kinetics of purified VLPs was monitored in real time. Evidence supporting the mechanism that the correct disulfide bond pairing is the molecular basis for shaping up the native virion-like epitopes was obtained. At least 10-fold enhancement in antigenicity probed by A1.2 of the VLPs was achieved by heat-treatment (t1/2 ∼ 6–10 h), and another 2- to 3-fold enhancement was obtained when they were treated with redox buffer. This antigenicity development, presumably via disulfide formation/isomerization, was shown to be inhibited by a free radical scavenger and facilitated in the presence of light. Relative antigenicity determination with surface plasmon resonance was shown to be a valuable tool for process characterization in the kinetic monitoring mode or for final VLP product assessment in the end point antigenicity testing mode. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining
- Author
-
Zhao, Qinjian, Guo, Helen H., Wang, Yang, Washabaugh, Michael W., and Sitrin, Robert D.
- Subjects
- *
OLIGOMERS , *PAPILLOMAVIRUSES , *ELECTROPHORESIS , *POLYACRYLAMIDE - Abstract
Abstract: The recombinant major capsid protein (L1) of human papillomavirus (HPV) can self-assemble into virus-like particles (VLPs) with 360 L1 molecules per VLP. These tightly associated L1 oligomers in the assembled VLPs were disrupted in a pH-, denaturant-, time-, and temperature-dependent fashion. With non-reducing Laemmli-type SDS-PAGE, primarily the monomeric L1 protein (∼55kDa) is observed when analyzing VLP preparations. When the pH was lowered to pH 7.0 in NuPAGE system and the gel temperature during electrophoresis was maintained at a lower temperature (∼7°C), a ladder of protein bands in ∼55kDa increments were detected above the monomeric p55 band. These discrete bands visualized as a ladder are likely the disulfide-linked L1 oligomers. In addition to the gel running conditions, an increase in pH, temperature, or SDS concentration during sample treatment was also shown to significantly reduce the amount of detectable oligomers, further corroborating the labile nature of these oligomers. Altogether, the results also implicate the redox-responsive nature of the HPV capsid comprising of >95% L1 protein. Molecular basis of the facile disulfide bond inter-change is discussed. This electrophoretic technique for trapping the disulfide-linked oligomers may be employed to detect the oligomeric status of other protein aggregates or assembled particles. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
8. NMR studies of the secondary structure in solution and the steroid binding site of...
- Author
-
Zhao, Qinjian and Abeygunawardana, Chitrananda
- Subjects
- *
ISOMERASES , *COMPLEX compounds , *STEROIDS , *CHEMICAL structure - Abstract
Reports on the nuclear magnetic resonance studies of the secondary structure in solution and the steroid binding site of ketosteroid isomerase in complexes with diamagnetic and paramagnetic steroids. Effects of doxyl-DHT on the H-15N HSQC spectrum of the enzyme; Enzyme-bound steroid in the normal binding mode for catalysis.
- Published
- 1997
- Full Text
- View/download PDF
9. 13C NMR relaxation studies of backbone and side chain motion of the catalytic tyrosine residue in...
- Author
-
Zhao, Qinjian and Abeygunawardana, Chitranada
- Subjects
- *
TYROSINE , *ISOMERASES - Abstract
Studies the backbone and side chain motion of the catalytic tyrosine residue in free and steroid-bound ketosteroid isomerase. NMR spectroscopy; Preparation of NMR samples; Protein purification and sample preparation; Relaxation theory; Dynamical parameters for high-frequency motion of Tyr-14 in free and liganded isomerases.
- Published
- 1996
- Full Text
- View/download PDF
10. Ultraviolet spectroscopic evidence for decreased motion of the active site tyrosine residue of...
- Author
-
Zhao, Qinjian and Li, Yaw-Kuen
- Subjects
- *
ISOMERASES , *TYROSINE , *PSEUDOMONAS , *REACTIVITY (Chemistry) - Abstract
Presents evidence for decreased motion of the active site of tyrosine residue of delta5-3-ketosteroid isomerase from Pseudomonas testosteroni. Use of the isomerase to catalyze the conversion of delta5-3-ketosteroids; Determination of the ultraviolet absorption bandwidths.
- Published
- 1995
- Full Text
- View/download PDF
11. Ultraviolet resonance Raman spectroscopy of delta5-3-ketosteroid isomerase revisited: Substrate...
- Author
-
Austin, Janina C. and Zhao, Qinjian
- Subjects
- *
ISOMERASES , *RAMAN spectroscopy - Abstract
Reexamines the ultraviolet Raman spectroscopy of delta-3-ketosteroid isomerase. Hydrogen bonding and protonation of 19-nortestoterone in aqueous acid; Steroid polarization by wild-type and mutant isomerase; Hydrogen-bond compensation.
- Published
- 1995
- Full Text
- View/download PDF
12. Enzymatic and nonenzymatic polarizations of alpha, beta-unsaturated ketosteroids and phenolic...
- Author
-
Zhao, Qinjian and Mildvan, Albert S.
- Subjects
- *
STEROIDS , *PHENOLS , *SCIENTIFIC experimentation - Abstract
Reports effects of the medium on the UV and fluorescence spectral properties of alpha, beta-unsaturated ketosteroids and phenolic compounds. Comparison of these properties to those of enzyme-bound steroids; Experimental procedures, results and discussion; Explanation of spectral findings by strong, directional hydrogen bonding interaction between Tyr-14 and steroid ligands in solvent-inaccessible active site.
- Published
- 1995
- Full Text
- View/download PDF
13. Enantioselective and reversible inhibition of trypsin and alpha-chymotrypsin by phosphonate esters.
- Author
-
Zhao, Qinjian and Kovach, Ildiko M.
- Subjects
- *
CHYMOTRYPSIN , *TRYPSIN inhibitors , *SERINE proteinases , *ENANTIOMERS , *CHEMICAL inhibitors - Abstract
Reveals efficient inactivation of serine proteases with great enantiomeric selectivity that reflect binding affinities. Inactivation of trypsin by levorotatory enantiomers; Second-order rate constants for the inactivation of alpha-chymotrypsin; Principal interaction between phosphonyl groups and constituents of the oxyanion hole.
- Published
- 1994
- Full Text
- View/download PDF
14. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to...
- Author
-
Zhao, Qinjian and Yang, Xiao Ling
- Subjects
- *
OXIDOREDUCTASES , *FLAVOPROTEINS , *CHEMICAL structure - Abstract
Shows that NAD(P)H:(quinone acceptor) oxidoreductase or DT-diaphorase (QR1) and quinone reductase type 2 (QR2) are closely related in sequence and structure. QR activity of protein encoded by cDNA clone when tested with conventional nicotinamide nucleotides; Properties of hQR2 and flavoenzyme; X-ray crystal structure of QR1.
- Published
- 1997
- Full Text
- View/download PDF
15. NMR evidence for the participation of a low-barrier hydrogen bond in mechanism of delta5-3-...
- Author
-
Zhao, Qinjian and Abeygunawardana, Chitrananda
- Subjects
- *
NUCLEAR magnetic resonance , *HYDROGEN bonding , *ISOMERASES - Abstract
Studies the direct nuclear magnetic resonance (NMR) spectral evidence for the existence of a low-barrier hydrogen bond (LBHB) between the acid catalyst, Tyr-14, and the dienolic intermediate of isomerase. Detection of deshielded resonance by the binding of the dienolate to isomerase; LBHB's role on stabilization and catalytic power of the enzyme.
- Published
- 1996
- Full Text
- View/download PDF
16. Rate-determining carbonyl hydration in the intramolecular hydrolysis of phenacyl phosphonate...
- Author
-
Kovach, Ildiko M. and Zhao, Qinjian
- Subjects
- *
PHOSPHONATES , *ESTERS - Abstract
Studies the isotopic probes and activation parameters in the rate-determining carbonyl hydration in the intramolecular hydrolysis of phenacyl phosphonate esters. Decomposition of 4-nitrophenyl 4-substituted-phenacyl methylphosphonate esters in aqueous buffers compared to analogs with alkoxy substituents without a beta-carbonyl group; Activation parameters.
- Published
- 1993
- Full Text
- View/download PDF
17. Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy.
- Author
-
Zhang, Xiuli, Wei, Mingjing, Zhang, Zhigang, Zeng, Yarong, Zou, Feihong, Zhang, Sibo, Wang, Zhiping, Chen, Fentian, Xiong, Hualong, Li, Yufang, Zhou, Lizhi, Li, Tingting, Zheng, Qingbing, Yu, Hai, Zhang, Jun, Gu, Ying, Zhao, Qinjian, Li, Shaowei, and Xia, Ningshao
- Subjects
- *
CANCER vaccines , *CELL surface antigens , *ANTIGEN presenting cells , *HUMORAL immunity , *CELLULAR immunity - Abstract
The cGAS-STING pathway and the Mevalonate Pathway are druggable targets for vaccine adjuvant discovery. Manganese (Mn) and bisphosphonates are known to exert adjuvant effects by targeting these two pathways, respectively. This study found the synergistic potential of the two pathways in enhancing immune response. Risedronate (Ris) significantly amplified the Mn adjuvant early antibody response by 166-fold and fortified its cellular immunity. However, direct combination of Mn2+ and Ris resulted in increased adjuvant toxicity (40% mouse mortality). By the combination of doping property of hydroxyapatite (HA) and its high affinity for Ris, we designed Ris-functionalized Mn-HA micro-nanoparticles as an organic-inorganic hybrid adjuvant, named MnHARis. MnHARis alleviated adjuvant toxicity (100% vs. 60% survival rate) and exhibited good long-term stability. When formulated with the varicella-zoster virus glycoprotein E (gE) antigen, MnHARis triggered a 274.3-fold increase in IgG titers and a 61.3-fold surge in neutralization titers while maintaining a better long-term humoral immunity compared to the aluminum adjuvant. Its efficacy spanned other antigens, including ovalbumin, HPV18 VLP, and SARS-CoV-2 spike protein. Notably, the cellular immunity elicited by the group of gE + MnHARis was comparable to the renowned Shingrix®. Moreover, intratumoral co-administration with an anti-trophoblast cell surface antigen 2 nanobody revealed synergistic antitumor capabilities. These findings underscore the potential of MnHARis as a potent adjuvant for augmenting vaccine immune responses and improving cancer immunotherapy outcomes. Risedronate (Ris)-functionalized manganese (Mn2+)-HA adjuvant was designed, named MnHARis. The Mn2+ and Ris co-dopion successfully transformed HA crystalline rodlike precipitation into Mn/CaRis amorphous precipitates. MnHARis enhanced antigen presenting cells (APCs) activation and induced robust humoral and cellular immunity in subunit vaccines. Moreover, MnHARis demonstrated a synergistic anti-cancer effect when co-administered intratumorally with nanobody. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China.
- Author
-
Lin, Yulan, Hu, Zhijian, Zhao, Qinjian, Alias, Haridah, Danaee, Mahmoud, and Wong, Li Ping
- Subjects
- *
COVID-19 vaccines , *COVID-19 , *HEALTH Belief Model , *VACCINE safety , *VACCINE hesitancy - Abstract
Background: This study attempts to understand coronavirus disease 2019 (COVID-19) vaccine demand and hesitancy by assessing the public's vaccination intention and willingness-to-pay (WTP). Confidence in COVID-19 vaccines produced in China and preference for domestically-made or foreign-made vaccines was also investigated. Methods: A nationwide cross-sectional, self-administered online survey was conducted on 1–19 May 2020. The health belief model (HBM) was used as a theoretical framework for understanding COVID-19 vaccination intent and WTP. Results: A total of 3,541 complete responses were received. The majority reported a probably yes intent (54.6%), followed by a definite yes intent (28.7%). The perception that vaccination decreases the chances of getting COVID-19 under the perceived benefit construct (OR = 3.14, 95% CI 2.05–4.83) and not being concerned about the efficacy of new COVID-19 vaccines under the perceived barriers construct (OR = 1.65, 95% CI 1.31–2.09) were found to have the highest significant odds of a definite intention to take the COVID-19 vaccine. The median (interquartile range [IQR]) of WTP for COVID-19 vaccine was CNY¥200/US$28 (IQR CNY¥100–500/USD$14–72). The highest marginal WTP for the vaccine was influenced by socio-economic factors. The majority were confident (48.7%) and completely confident (46.1%) in domestically-made COVID-19 vaccine. 64.2% reported a preference for a domestically-made over foreign-made COVID-19 vaccine. Conclusions: The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intent and WTP. It is important to improve health promotion and reduce the barriers to COVID-19 vaccination. Author summary: This study investigated vaccine demand and hesitancy by assessing the intention to vaccinate against COVID-19 and willingness-to-pay. We found that a considerable proportion of the public in China has a definite intention to receive the COVID-19 vaccine; a higher proportion expressed a probable intention. Perceived benefits and barriers to vaccination (namely vaccine efficacy and adverse event concerns) of the health belief model constructs were significant predictors of COVID-19 vaccination intent. A substantial proportion was concerned about fake or faulty COVID-19 vaccines; however, this was not a significant predictor of vaccination intention. The willingness-to-pay for the COVID-19 was determined and was found to be positively associated with income. Higher confidence in domestically-made COVID-19 vaccines was also found in this study. The preference for domestically-made over foreign-made COVID-19 vaccines indicates that a future COVID-19 vaccine developed by domestic companies will receive a favourable response from the public in China.The findings of this study provide useful guidance for tailored interventions to enhance the acceptance of a new COVID-19 vaccine once it is available. Promotional messages framing the benefit of vaccination and concerns about new vaccine safety to enhance vaccine uptake is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents.
- Author
-
Zhong, Ling, Zhang, Wanlin, Krummenacher, Claude, Chen, Yixin, Zheng, Qingbing, Zhao, Qinjian, Zeng, Mu-Sheng, Xia, Ningshao, Zeng, Yi-Xin, Xu, Miao, and Zhang, Xiao
- Subjects
- *
GLYCOPROTEINS , *HERPESVIRUSES , *VARICELLA-zoster virus , *LATENT infection , *VACCINE development , *VACCINE effectiveness , *VIRAL envelope proteins - Abstract
At the core entry process of human herpesviruses (HHVs), the glycoprotein H and L (gHgL)-based entry complex (EC) induces conformational change (pre- to post-fusion) of the fusogen glycoprotein B (gB). Vaccines and neutralizing antibodies (nAbs) against EC and gB are tested in clinical trials to prevent HHV infection. New structures of pre-gB are shorter with different arrangements of domains compared to post-gB. From pre-gB to post-gB transition, domain I, II, and V flip around the center, while buried domian IV is exposed to form a crown. Vaccines comprising pre-gB are predicted to be more effective. The structures of ECs and their receptors continue to be determined, further uncovering new neutralizing epitopes and mechanisms while characterizing the molecular processes of HHV entry. Structure-based approaches in vaccine design include stabilizing pre-gB, refining the fusion signal transmission model, and identifying more potent nAbs. Herpesviruses are among the most successful viruses found in human populations. They establish lifelong latent infections, which are punctuated by recurrent reactivations. The entry process of herpesviruses into specific target cells requires a well-orchestrated teamwork involving multiple envelope glycoproteins. The conserved glycoprotein B (gB) is the membrane fusogen, of which conformational changes are induced by an entry complex (EC) consisting of at least gH and gL. Despite the high prevalence and heavy disease burdens associated with human herpesviruses (HHVs), vaccines against these pathogens are still lacking, except for varicella zoster virus (VZV). Recent advances in understanding the coordinated mechanisms of action of the key EC glycoproteins and fusogen will help to improve approaches for effective vaccine development and neutralizing antibody (nAb) screening. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Modulation of Skin Inflammatory Responses by Aluminum Adjuvant.
- Author
-
Liao, Yanhang, Sun, Lixiang, Nie, Meifeng, Li, Jiacheng, Huang, Xiaofen, Heng, Shujun, Zhang, Wenlu, Xia, Tian, Guo, Zhuolin, Zhao, Qinjian, and Zhang, Ling-juan
- Subjects
- *
INFLAMMATION , *ALUMINUM , *SKIN inflammation , *NEUTROPHILS , *PERITONEAL macrophages , *BONE marrow , *ALUMINUM foam - Abstract
Aluminum salt (AS), one of the most commonly used vaccine adjuvants, has immuno-modulatory activity, but how the administration of AS alone may impact the activation of the skin immune system under inflammatory conditions has not been investigated. Here, we studied the therapeutic effect of AS injection on two distinct skin inflammatory mouse models: an imiquimod (IMQ)-induced psoriasis-like model and an MC903 (calcipotriol)—induced atopic dermatitis-like model. We found that injection of a high dose of AS not only suppressed the IMQ-mediated development of T-helper 1 (Th1) and T-helper 17 (Th17) immune responses but also inhibited the IMQ-mediated recruitment and/or activation of neutrophils and macrophages. In contrast, AS injection enhanced MC903-mediated development of the T-helper 2 (Th2) immune response and neutrophil recruitment. Using an in vitro approach, we found that AS treatment inhibited Th1 but promoted Th2 polarization of primary lymphocytes, and inhibited activation of peritoneal macrophages but not bone marrow derived neutrophils. Together, our results suggest that the injection of a high dose of AS may inhibit Th1 and Th17 immune response-driven skin inflammation but promote type 2 immune response-driven skin inflammation. These results may provide a better understanding of how vaccination with an aluminum adjuvant alters the skin immune response to external insults. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Omics-guided bacterial engineering of Escherichia coli ER2566 for recombinant protein expression.
- Author
-
Zhou, Lizhi, Ma, Yue, Wang, Kaihang, Chen, Tingting, Huang, Yang, Liu, Liqin, Li, Yuqian, Sun, Jie, Hu, Yisha, Li, Tingting, Kong, Zhibo, Wang, Yingbin, Zheng, Qingbing, Zhao, Qinjian, Zhang, Jun, Gu, Ying, Yu, Hai, Xia, Ningshao, and Li, Shaowei
- Subjects
- *
RECOMBINANT proteins , *PROTEIN expression , *ESCHERICHIA coli , *GENE expression - Abstract
The goal of bacterial engineering is to rewire metabolic pathways to generate high-value molecules for various applications. However, the production of recombinant proteins is constrained by the complexity of the connections between cellular physiology and recombinant protein synthesis. Here, we used a rational and highly efficient approach to improve bacterial engineering. Based on the complete genome and annotation information of the Escherichia coli ER2566 strain, we compared the transcriptomic profiles of the strain under leaky expression and low temperature-induced stress. Combining the gene ontology (GO) enrichment terms and differentially expressed genes (DEGs) with higher expression, we selected and knocked out 36 genes to determine the potential impact of these genes on protein production. Deletion of bluF, cydA, mngR, and udp led to a significant decrease in soluble recombinant protein production. Moreover, at low-temperature induction, 4 DEGs (gntK, flgH, flgK, flgL) were associated with enhanced expression of the recombinant protein. Knocking out several motility-related DEGs (ER2666-ΔflgH-ΔflgL-ΔflgK) simultaneously improved the protein yield by 1.5-fold at 24 °C induction, and the recombinant strain had the potential to be applied in the expression studies of different exogenous proteins, aiming to improve the yields of soluble form to varying degrees in comparison to the ER2566 strain. Totally, this study focused on the anabolic and stress-responsive hub genes of the adaptation of E. coli to recombinant protein overexpression on the transcriptome level and constructs a series of engineering strains increasing the soluble protein yield of recombinant proteins which lays a solid foundation for the engineering of bacterial strains for recombinant technological advances. Key points: • Comparative transcriptome analysis shows host responses with altered induction stress. • Deletion of bluF, cydA, mngR, and udp genes was identified to significantly decrease the soluble recombinant protein productions. • Synchronal knockout of flagellar genes in E. coli can enhance recombinant protein yield up to ~ 1.5-fold at 24 °C induction. • Non-model bacterial strains can be re-engineered for recombinant protein expression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus.
- Author
-
Zhong, Ling, Krummenacher, Claude, Zhang, Wanlin, Hong, Junping, Feng, Qisheng, Zhao, Qinjian, Chen, Yixin, Zeng, Mu-Sheng, Zeng, Yi-Xin, Xu, Miao, and Zhang, Xiao
- Subjects
- *
MONOCLONAL antibodies , *EPSTEIN-Barr virus , *IMMUNOGLOBULINS , *MONONUCLEOSIS , *EPITHELIAL cells - Abstract
Background: Epstein-Barr virus (EBV) is a wide-spread human herpesvirus that is highly associated with infectious mononucleosis and several malignancies. Evaluation of EBV neutralizing antibody titers is important for serological studies, vaccine development and monoclonal antibody screening. The traditional method based on antibody inhibition of EBV transformation of B cells is very time-consuming. A more practical flow cytometry-based (FCM) approach to evaluate neutralizing titers is not amenable to achieving high-throughput evaluation of large-scale samples. A high-throughput approach is urgently needed. Results: Here, we present a rapid and high-throughput method based on high content imaging system (HCIS) analysis. EBV titers determined by the HCIS-based assay were similar to those obtained by the FCM-based assay. Neutralizing titers of sera and monoclonal antibodies measured by the HCIS-based assay strongly correlated with titers measured by the FCM-based assay. HCIS assays showed a strong correlation between B cell infection neutralizing titers and the anti-gp350 IgG titers in healthy EBV carriers and monkey sera. Finally, anti-gHgL IgG titers from sera of healthy EBV carriers significantly correlated with epithelial cell infection neutralizing titers. Conclusions: This HCIS-based assay is a high-throughput assay to determine viral titers and evaluate neutralizing potentials of sera and monoclonal antibodies. This HCIS-based assay will aid the development of vaccines and therapeutic monoclonal antibody against EBV. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.
- Author
-
Deng, Tingting, Li, Tingting, Chen, Gege, Zhu, Yuhe, Xu, Lang, Lin, Yanlin, Sun, Hui, Zhang, Hui, Fang, Qianjiao, Hong, Junping, Wu, Dinghui, Gao, Shuangquan, Li, Shaoyong, Wang, Yingbin, Zhang, Tianying, Chen, Yixin, Yuan, Quan, Zheng, Qingbing, Yu, Hai, and Zhao, Qinjian
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *IMMUNE response , *GLUTATHIONE transferase , *GLYCOSYLATION , *CONVALESCENT plasma - Abstract
• Optimized the expression of the S-2P protein in 293F cells, and obtained a 5-times higher yield. • Different glycosylated S-2P proteins varied in physiochemical properties, antigenicity and immunogenicity. • S-2P proteins from 293 cells induced a more potent nAb response than did proteins produced from insect cells. • Priming with 293S S-2P and then boosting with Bac S-2P and then 293F S-2P can elicit a higher nAb response than with a single S-2P alone. The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drastically changed our way of life and continues to have an unmitigated socioeconomic impact across the globe. Research into potential vaccine design and production is focused on the spike (S) protein of the virus, which is critical for virus entry into host cells. Yet, whether the degree of glycosylation in the S protein is associated with vaccine efficacy remains unclear. Here, we first optimized the expression of the S protein in mammalian cells. While we found no significant discrepancy in purity, homogeneity, or receptor binding ability among S proteins derived from 293F cells (referred to as 293F S-2P), 293S GnTI- cells (defective in N -acetylglucosaminyl transferase I enzyme; 293S S-2P), or TN-5B1-4 insect cells (Bac S-2P), there was significant variation in the glycosylation patterns and thermal stability of the proteins. Compared with the partially glycosylated 293S S-2P or Bac S-2P, the fully glycosylated 293F S-2P exhibited higher binding reactivity to convalescent sera. In addition, 293F S-2P induced higher IgG and neutralizing antibody titres than 293S or Bac S-2P in mice. Furthermore, a prime-boost-boost regimen, using a combined immunization of S-2P proteins with various degrees of glycosylation, elicited a more robust neutralizing antibody response than a single S-2P alone. Collectively, this study provides insight into ways to design a more effective SARS-CoV-2 immunogen. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Microtiter Plate-Based Differential Scanning Fluorimetry: A High-Throughput Method for Efficient Formulation Development.
- Author
-
Nie, Meifeng, Liu, Yue, Huang, Xiaofen, Zhang, Zhigang, and Zhao, Qinjian
- Subjects
- *
MICROPLATES , *FLUORIMETRY , *TITERS , *DIFFERENTIAL scanning calorimetry , *PROTEIN stability , *PROTEIN models , *THERMAL stability - Abstract
• A fluorescence-based DSF provides rapid assessment of adjuvant-adsorbed protein in a microplate format. • The effect of multi-factors in formulation development can be well-explored using smaller sample amount than DSC. • Good correlation of the results from well-established DSC and from high-throughput, automation amenable DSF is observed. Nano/microparticles are widely used as vaccine adjuvants to improve antigen stability and enhance immune response. Conformational stability of a given protein was normally assessed using differential scanning calorimetry (DSC) for the optimization of formulation and for ensuring antigen stability in vaccine products. Here, a higher throughput version, namely the microtiter plate-based differential scanning fluorimetry (DSF) method was developed and optimized for assessing the protein thermal stability in the particulate adjuvant-adsorbed form. Using recombinant human papillomavirus (HPV) vaccine antigens, along with several model proteins, enhanced sensitivity and correlation to the well-established differential scanning calorimetry were demonstrated. Higher throughput and much smaller sample consumption (1/10 ∼ 1/20 of the amount needed as compared to DSC) make the plate-based DSF a method of choice for formulation development, particularly during the early developmental phase of a project where the sample amount is usually quite limited. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries.
- Author
-
Wong, Li Ping, Alias, Haridah, Danaee, Mahmoud, Ahmed, Jamil, Lachyan, Abhishek, Cai, Carla Zi, Lin, Yulan, Hu, Zhijian, Tan, Si Ying, Lu, Yixiao, Cai, Guoxi, Nguyen, Di Khanh, Seheli, Farhana Nishat, Alhammadi, Fatma, Madhale, Milkar D., Atapattu, Muditha, Quazi-Bodhanya, Tasmi, Mohajer, Samira, Zimet, Gregory D., and Zhao, Qinjian
- Subjects
- *
COVID-19 vaccines , *VACCINATION complications , *VACCINE hesitancy , *VACCINATION , *COVID-19 pandemic , *HOOKAHS - Abstract
Background: The availability of various types of COVID-19 vaccines and diverse characteristics of the vaccines present a dilemma in vaccination choices, which may result in individuals refusing a particular COVID-19 vaccine offered, hence presenting a threat to immunisation coverage and reaching herd immunity. The study aimed to assess global COVID-19 vaccination intention, vaccine characteristics influencing vaccination acceptance and desirable vaccine characteristics influencing the choice of vaccines. Methods: An anonymous cross-sectional survey was conducted between 4 January and 5 March 2021 in 17 countries worldwide. Proportions and the corresponding 95% confidence intervals (CI) of COVID-19 vaccine acceptance and vaccine characteristics influencing vaccination acceptance were generated and compared across countries and regions. Multivariable logistic regression analysis was used to determine the factors associated with COVID-19 vaccine hesitancy. Results: Of the 19,714 responses received, 90.4% (95% CI 81.8–95.3) reported likely or extremely likely to receive COVID-19 vaccine. A high proportion of likely or extremely likely to receive the COVID-19 vaccine was reported in Australia (96.4%), China (95.3%) and Norway (95.3%), while a high proportion reported being unlikely or extremely unlikely to receive the vaccine in Japan (34.6%), the U.S. (29.4%) and Iran (27.9%). Males, those with a lower educational level and those of older age expressed a higher level of COVID-19 vaccine hesitancy. Less than two-thirds (59.7%; 95% CI 58.4–61.0) reported only being willing to accept a vaccine with an effectiveness of more than 90%, and 74.5% (95% CI 73.4–75.5) said they would accept a COVID-19 vaccine with minor adverse reactions. A total of 21.0% (95% CI 20.0–22.0) reported not accepting an mRNA vaccine and 51.8% (95% CI 50.3–53.1) reported that they would only accept a COVID-19 vaccine from a specific country‐of‐origin. Countries from the Southeast Asia region reported the highest proportion of not accepting mRNA technology. The highest proportion from Europe and the Americas would only accept a vaccine produced by certain countries. The foremost important vaccine characteristic influencing vaccine choice is adverse reactions (40.6%; 95% CI 39.3–41.9) of a vaccine and effectiveness threshold (35.1%; 95% CI 33.9–36.4). Conclusions: The inter-regional and individual country disparities in COVID-19 vaccine hesitancy highlight the importance of designing an efficient plan for the delivery of interventions dynamically tailored to the local population. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Replication, pathogenicity, and transmission of SARS-CoV-2 in minks.
- Author
-
Shuai, Lei, Zhong, Gongxun, Yuan, Quan, Wen, Zhiyuan, Wang, Chong, He, Xijun, Liu, Renqiang, Wang, Jinliang, Zhao, Qinjian, Liu, Yuxiu, Huo, Ningning, Deng, Junhua, Bai, Jingjing, Wu, Hongchao, Guan, Yuntao, Shi, Jianzhong, Tian, Kegong, Xia, Ningshao, Chen, Hualan, and Bu, Zhigao
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *DRUG efficacy - Abstract
Minks are raised in many countries and have transmitted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to humans. However, the biologic properties of SARS-CoV-2 in minks are largely unknown. Here, we investigated and found that SARS-CoV-2 replicates efficiently in both the upper and lower respiratory tracts, and transmits efficiently in minks via respiratory droplets; pulmonary lesions caused by SARS-CoV-2 in minks are similar to those seen in humans with COVID-19. We further found that a spike protein-based subunit vaccine largely prevented SARS-CoV-2 replication and lung damage caused by SARS-CoV-2 infection in minks. Our study indicates that minks are a useful animal model for evaluating the efficacy of drugs or vaccines against COVID-19 and that vaccination is a potential strategy to prevent minks from transmitting SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Global vaccine action plan lessons learned I: Recommendations for the next decade.
- Author
-
MacDonald, Noni, Mohsni, Ezzeddine, Al-Mazrou, Yagob, Kim Andrus, Jon, Arora, Narendra, Elden, Susan, Madrid, Marie-Yvette, Martin, Rebecca, Mahmoud Mustafa, Amani, Rees, Helen, Salisbury, David, Zhao, Qinjian, Jones, Ian, Steffen, Christoph A., Hombach, Joachim, O'Brien, Katherine L., and Cravioto, Alejandro
- Subjects
- *
LESSON planning , *VACCINES , *IMMUNIZATION - Abstract
• GVAP provided a comprehensive and coherent global framework for immunization. • Much progress was achieved under GVAP, although most GVAP goals will not be met. • GVAP was perceived as top-down, with too little consideration of country context. • GVAP was only partially implemented, and it had limited levers to influence country actions. • Many targets were seen as unrealistic, particularly in the absence of additional funding. • Lessons learned from GVAP can inform the Immunization Agenda 2030. The Global Vaccine Action Plan 2011–2020 (GVAP) was developed to realize the ambitions of the Decade of Vaccines – that all individuals and communities enjoy lives free from vaccine-preventable diseases. It included a comprehensive monitoring and evaluation/accountability framework to assess progress towards global targets with recommendations for corrective actions. While many of the GVAP targets are very unlikely to be met by the end of 2020, substantial progress has nevertheless been made, establishing a strong foundation for a successor global immunization strategy, the Immunization Agenda 2030 (IA2030). The Strategic Advisory Group of Experts on immunization has made a series of recommendations to ensure that the lessons learned from GVAP inform the development and implementation of IA2030. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. The study of seroprevalence of hepatitis E virus and an investigation into the lifestyle behaviours of the aborigines in Malaysia.
- Author
-
Wong, Li Ping, Alias, Haridah, Choy, Seow Huey, Goh, Xiang Ting, Lee, Soo Ching, Lim, Yvonne Ai Lian, Kee, Boon Pin, Chua, Kek Heng, Kamaruzaman, Adeeba, Zheng, Zizheng, Zhao, Qinjian, and Wu, Ting
- Subjects
- *
HEPATITIS E virus , *INDIGENOUS peoples , *SEROPREVALENCE , *FOOD contamination , *WASTE management , *RESEARCH implementation - Abstract
Malaysia is a non‐endemic country for hepatitis E virus (HEV) infection. However, seroprevalence as high as 50% among samples of aboriginal people were reported over two decades ago. A total of 207 samples collected from seven aboriginal villages in rural settlements across two states in Malaysia were analysed for anti‐HEV IgG and IgM by an enzyme‐linked immunoassay. Following the detection of anti‐HEV seroprevalence, we organized health outreach to inform and educate the community. Qualitative interviews were conducted with individuals tested positive for anti‐HEV antibodies. Data derived from interviews and observations were used to investigate possible lifestyle behaviours associated with HEV infection. Anti‐HEV IgG was detected in six samples (5.9%) from the village of Dusun Kubur. Qualitative inquiry and observation study revealed poor dietary and household hygiene, contaminated food and water, contact with animal faeces, unsanitary and domestic waste disposal, and wildlife reservoirs could be the contributing factors for transmission and acquisition of HEV infection. Investigation during health outreach is important to provide insights for future empirical research and implementation for improvement of lifestyle behaviours among the aborigines. Managing the risk of HEV infection in the aborigines may reduce the risk of HEV transmission to the local communities. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. HIV-1 Membrane-Proximal External Region Fused to Diphtheria Toxin Domain-A Elicits 4E10-Like Antibodies in Mice.
- Author
-
Zhang, Zhiqing, Wei, Xiang, Lin, Yanling, Huang, Fang, Shao, Jia, Qi, Jialong, Deng, Tingting, Li, Zizhen, Gao, Shuangquan, Li, Shaoyong, Yu, Hai, Zhao, Qinjian, Li, Shaowei, Gu, Ying, and Xia, Ningshao
- Subjects
- *
DIPHTHERIA toxin , *IMMUNOGLOBULINS , *MONOCLONAL antibodies , *LABORATORY mice , *HIV infections , *VIRAL vaccines - Abstract
• HIV-1 MPER fused to the Diphtheria Toxin Domain A was immunogenic in BALB/c mice. • The fusion proteins exhibited good reactivity with bNAb 2F5 and 4E10. • Monoclonal antibodies isolated from the CRM197-A-4E10 immunized mice conferred cross-clade neutralizing activity. • Epitope-mapping analysis suggested the monoclonal antibodies share key epitope residues with bNAb 4E10. The production of broadly neutralizing antibodies (bNAbs) is a major goal in the development of an HIV-1 vaccine. The membrane-proximal external region (MPER) of gp41, which plays a critical role in the virus membrane fusion process, is highly conserved and targeted by bNAbs 2F5, 4E10, and 10E8. As such, MPER could be a promising epitope for vaccine design. In this study, diphtheria toxin domain A (CRM197, amino acids 1–191) was used as a scaffold to display the 2F5 and 4E10 epitopes of MPER, named CRM197-A-2F5 and CRM197-A-4E10. Modest neutralizing activities were detected against HIV-1 clade B and D viruses in the sera from mice immunized with CRM197-A-4E10. Monoclonal antibodies raised from CRM197-A-4E10 could neutralize several HIV-1 strains, and epitope-mapping analysis indicated that some antibodies recognized the same amino acids as 4E10. Collectively, we show that 4E10-like antibodies can be induced by displaying MPER epitopes using an appropriate scaffold. These results provide insights for HIV-1 MPER-based immunogens design. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.
- Author
-
Chen, Siyi, Huang, Xiaofen, Li, Yike, Wang, Xin, Pan, Huirong, Lin, Zhijie, Zheng, Qingbing, Li, Shaowei, Zhang, Jun, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
VIRUS-like particles , *HEPATITIS E virus , *PROTEIN stability , *MONOCLONAL antibodies , *THERAPEUTICS - Abstract
• Different epitopes showed different levels of sensitivity to thimerosal treatment. • Reduced conformational stability of HPV antigens in the presence of thimerosal. • Reduced immunogenicity of HPV16 and HPV18 VLPs after thimerosal treatment. • Altered structure of the recombinant HPV18 capsids due to thimerosal treatment. • Thiol modification is likely the basis for structural and functional alterations. Thimerosal has been widely used as a preservative in human vaccines for decades. Thimerosal, a thiol capping agent with ethyl mercury being the active degradant, could have impacts on the vaccine potency due to potential thiol modification. The effects on the antigenicity and immunogenicity of human papillomavirus (HPV) virus-like particles (VLPs) in the presence of thimerosal was studied. In general, reduced binding activity was observed between HPV antigens and monoclonal antibodies (mAbs) upon thimerosal treatment, accompanied by reduced protein conformational stability. The immunogenicity of a pentavalent vaccine formulation (HPV6, HPV11, HPV16, HPV18 and hepatitis E virus) with or without thimerosal was studied in mice. The functional antibody titres, as well as the binding titres, were determined, showing a substantial decrease for vaccine formulations containing thimerosal for HPV16/18. Similarly, epitope-specific competition assays using specific and functional mAbs as tracers also showed a significant reduction in immunogenicity for HPV16/18 in the presence of thimerosal. Structural alterations in the capsid protein for HPV18 were observed with cryo-electron microscopy and 3-dimensional reconstruction in the comparative structural analysis. The results should alert scientists in formulation development field on the choice for vaccine preservatives, in particular for thiol-containing antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
- Author
-
Wang, Kaihang, Zhou, Lizhi, Zhang, Xiao, Song, Cuiling, Chen, Tingting, Li, Jiajia, Zheng, Minghua, Wang, Yingbin, Zheng, Qingbing, Zheng, Zizheng, Yu, Hai, Wu, Ting, Gu, Ying, Zhang, Jun, Zhao, Qinjian, Li, Shaowei, and Xia, Ningshao
- Subjects
- *
HEPATITIS E , *MONOCLONAL antibodies , *HEPATITIS E vaccines - Abstract
Abstract The Hepatitis E vaccine (Hecolin, licensed in China) harbors a potent particulate immunogen, p239, designed from a 26-aa N-terminal extension of its poorly immunogenic parental protein, E2. Although an effective vaccine, we sought to design a fusion protein in a non-particulate form that could improve the delivery and immunogenicity of E2 epitopes. The non-toxic mutant of diphtheria toxin, CRM197 (Cross-Reacting Material 197) has been successfully used as a carrier protein for conjugated vaccines to enhance the immunogenicity of polysaccharides. Here, we designed a fusion non-particulate protein of E2 and the catalytic domain (fragment A) of CRM197 and evaluated its antigenicity, immunogenicity and disease prevention efficacy in primates. This fusion protein, named CRM197(A)-E2, was bacterially expressed and purified by chromatography. CRM197(A)-E2 presented as a homodimer in solution, similar to its parental E2 protein, and exhibited excellent antigenicity against representative neutralizing monoclonal antibodies, like E2 and p239. However, CRM197(A)-E2 manifested higher immunogenicity in mice compared with that achieved by the particulate p239, as indicated by the 10-times lower ED 50 value and 2-log higher HEV-specific antibody level that could persist for at least 28 weeks. In addition, both the 1 μg and 10 μg doses of CRM197(A)-E2 adjuvanted with aluminum could protect vaccinated monkeys against HEV challenge, matching that achieved with only the higher (10 μg) dose of the p239 vaccine. These results suggest that the CRM197 fragment A alone serves as an intra-molecular adjuvant to remarkably enhance the immunogenicity of the target of interest in a non-particulate form. These findings may pave the way for rational vaccine design, especially in cases where particulates are not accessible. Highlights • The catalytic domain (fragment A) of CRM197 acts as an intra-molecular adjuvant. • Fusion protein CRM197(A)-E2 associates into a homodimer in solution, like E2. • CRM197(A)-E2 maintains the same major neutralization epitopes as E2 and p239. • CRM197(A)-E2 shows 10-times higher immunogenicity than particulate p239 in mice. • CRM197(A)-E2 confers comparable Hepatitis E protection as Hecolin in primates. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine.
- Author
-
Wang, Xin, Li, Min, Lin, Zhijie, Pan, Huirong, Tang, Zimin, Zheng, Zizheng, Li, Shaowei, Zhang, Jun, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
RECOMBINANT proteins , *EPITOPES , *THERMAL stability , *ALUMINUM , *MONOCLONAL antibodies , *HEPATITIS E vaccines - Abstract
Graphical abstract Highlights • Characterization of a panel of HEV mAbs using epitope clustering analysis. • Establishment of epitope-specific assays for antigen functional assessment. • Enhanced thermal stability of antigen when adsorbed onto aluminum-based adjuvant. • Essential immunochemical toolbox for vaccine development and manufacturing. • Assay orthogonality is based on different epitope interrogation in different formats. Abstract The integrity of functional epitopes is a critical quality attribute for recombinant protein based vaccines since the presence of these native-like epitopes is the structural basis for vaccines to elicit functional antibodies. To demonstrate the quality and quantity of functional epitopes on vaccine antigens, a toolbox of assessing antigen characteristics is essential. Among the physicochemical, biophysical, immunochemical and in vivo potency analyses, the epitope-specific assays are most critical assessment of the antigen functionality. In this study, we used hepatitis E virus vaccine as an example to illustrated how the monoclonal antibody (mAb) based immunochemical assays were established for in-depth and multifaceted antigen characterization. A large panel of mAbs were developed and characterized using epitope clustering analysis. A subset of these mAbs recognizing non-overlapping epitopes were chosen to be used for assay development. Orthogonal methods, including surface plasma resonance-based BIAcore, solution competitive ELISA and sandwich ELISA, were developed for the antigenicity assessment. The sandwich ELISA with a pair of mAbs, recognizing two different epitopes, was used to assess the accelerated antigen stability, showing enhanced stability with adjuvant adsorption. Such a sandwich ELISA with robust performance has the potentials to be used for in vitro potency analysis to replace animal-based potency assay as product release test. In summary, using hepatitis E vaccine as an example, we demonstrated the importance and establishment of a mAb-based immunochemical toolbox for multifaceted antigen characterization. This is particularly important to demonstrate the successful reconstruction of the native-like and functional epitopes on a recombinant antigen post expression and purification. These epitope-specific and multifaceted assays serve as critical tools for process monitoring or lot consistency tests in support of vaccine development and manufacturing. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.
- Author
-
Godi, Anna, Martinelli, Marianna, Haque, Mahmoud, Li, Shaowei, Zhao, Qinjian, Xia, Ningshao, Cocuzza, Clementina E, and Beddows, Simon
- Subjects
- *
PAPILLOMAVIRUSES , *CAPSIDS , *PROTEINS , *IMMUNOGLOBULINS , *LINEAGE - Abstract
Background: Naturally occurring variants of human papillomavirus (HPV) 58 have been defined as lineages and sublineages but little is known about the impact of this diversity on protein function. We investigated the impact of variation within the major (L1) and minor (L2) capsid proteins of HPV58 on susceptibility to neutralizing antibodies.Methods: Pseudovirus (PsV) representing A1, A2, A3, B1, B2, C, D1, and D2 variants were evaluated for their susceptibility to antibodies elicited during natural infection, preclinical antisera generated against virus-like particles, and monoclonal antibodies (MAbs).Results: Lineage C PsV demonstrated a decreased sensitivity to antibodies raised against lineage A antigens. Exchange of the DE, FG, and/or HI loops between sublineage A1 and lineage C demonstrated that residues within all 3 loops were essential for the differential sensitivity to natural infection antibodies, with slightly different requirements for the animal antisera and MAbs. Comparison between the HPV58 A1 L1 pentamer crystal structure and an HPV58 C homology model indicated that these differences in neutralization sensitivity were likely due to subtle epitope sequence changes rather that major structural alterations.Conclusions: These data improve our understanding of the impact of natural variation on HPV58 capsid antigenicity and raise the possibility of lineage-specific serotypes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
34. Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid.
- Author
-
Zhang, Cai, Huang, Xiaofen, Chen, Siyi, Li, Yike, Li, Yufang, Wang, Xin, Tang, Jixian, Xia, Lin, Lin, Zhijie, Luo, Wenxin, Li, Tingdong, Li, Shaowei, Zhang, Jun, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
HUMAN papillomavirus vaccines , *PAPILLOMAVIRUSES , *IMMUNOGLOBULINS , *MONOCLONAL antibodies , *CAPSIDS , *VIRUS-like particles , *EPITOPES , *VIRAL disease prevention - Abstract
Abstract Human papillomavirus (HPV) type 16 is the most common type implicated as the etiological agent that causes cervical cancer. The marketed prophylactic vaccines against HPV infection are composed of virus-like particles (VLPs) assembled from the recombinant major capsid protein L1. Elicitation of functional and neutralizing antibodies by vaccination is the mode of action by which the vaccines prevent the viral infection. In this study, a panel of murine mAbs against HPV16 L1 were generated and comprehensively characterized with respect to their mapping to the epitope spectrum on the viral capsid. These mAbs were categorized into five epitope bins by two different methods based on the pairwise cross-inhibition and competition with human polyclonal antibodies. In addition, a preliminary demonstration of the spatial relationship of the epitopes recognized by these mAbs was performed using a cross-blocking assay with a well-characterized human mAb, 26D1. Interestingly, two mAbs recognizing different epitopes were found to act synergistically in the pseudovirion-based neutralization assay (PBNA). To facilitate cross-lab and cross-study comparison, the international standard (IS) serum 05/134 was used to calibrate the mAbs as well as the human serum samples from the HPV16/18 vaccine recipients. The neutralizing mAbs, particularly those that recognizing immunodominant epitopes, would be useful in developing epitope-specific assays for monitoring the vaccine production process and for serological assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Precision and correlation of ED50 and endpoint titer method in measuring HPV vaccine immunogenicity.
- Author
-
Qiu, Dekui, Liu, Yue, Wang, Zhiping, Zhang, Zhigang, Nie, Meifeng, Xia, Ningshao, Li, Shaowei, and Zhao, Qinjian
- Subjects
- *
PAPILLOMAVIRUSES , *VACCINE immunogenicity , *HUMAN papillomavirus vaccines , *HUMAN papillomavirus , *ENZYME-linked immunosorbent assay , *TITERS - Abstract
Cervical cancer, the second leading cause of cancer-related deaths among women, is caused by human papillomavirus (HPV), a sexually transmitted virus. Vaccination is an effective preventive measure against viral infections and subsequent development of cervical cancer. Enzyme-linked immunosorbent assay (ELISA) is commonly used to measure specific binding antibody titers and assess the immunogenicity of test vaccines in preclinical models or clinical volunteers. Two methods of deriving titers, the endpoint titer (ET) and the effective dilution producing a median maximal effective fold of dilution (ED 50) with a cut-off value, are widely used. For HPV, a pseudovirion-based neutralization assay (PBNA) is used to measure functional antibody titers. The ELISA binding titers and functional PBNA titers were found to be well-correlated for all nine HPV types tested in the vaccine, consistent with previous studies on HPV 16/18. Comparing the PBNA results with the two titration methods, the ED 50 method showed higher precision and a closer correlation with PBNA results, both for individual types and pooled data analysis for all nine types. When comparing the titration results of the ET method based on a cut-off value with the ED 50 method using all the data points across the dilution series, the ED 50 method demonstrated better precision and a stronger correlation with PBNA results. • Mid-point vs. end point ELISA analysis showed improved precision of the former. • Higher coefficients were demonstrated with ED 50 method when correlating to PBNA. • The PBNA vs. ELISA correlation was confirmed for all 9 HPV vaccine types. • Mid-point method is a preferred method over the cut-off method in ELISA analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR.
- Author
-
You, Min, Yang, Yi, Zhong, Chuanqi, Chen, Fentian, Wang, Xin, Jia, Tianrong, Chen, Yuanzhi, Zhou, Bing, Mi, Qingyu, Zhao, Qinjian, An, Zhiqiang, Luo, Wenxin, and Xia, Ningshao
- Subjects
- *
IMMUNOGLOBULINS , *MASS spectrometry , *CHO cell , *GENE expression , *CHROMATOGRAPHIC analysis - Abstract
Antibody drugs have been used to treat a number of diseases successfully. Producing antibodies with high yield and quality is necessary for clinical applications of antibodies. For a candidate molecule, optimization of a vector to produce sufficient yield and an accurate primary structure is indispensable in the early stage of the production process development. It is especially important to maintain the fidelity of N-terminal sequence. In order to produce antibodies with a high yield and accurate N-terminal, the expression vector was systematically optimized in this study. First, the heavy chain and light chain were co-expressed in Chinese hamster ovary (CHO) cells with different signal peptides. Mass spectrometry (MS) revealed that signal peptides Esp-K, Bsp-H, and 8Hsp-H were accurately deleted from mature antibodies. Further, the yield was doubled by codon optimization and increased by 50% with the presence of untranslated regions (UTR). The combination of UTR with optimal codon and signal peptide to form an expression vector resulted in yield improvement of 150% and correct N-terminal sequences. Moreover, the main product peak was above 98% as assessed by size-exclusion chromatography (SEC). Additionally, the bioactivity of products made from optimized transient gene expression (TGE) was almost identical to the standard sample. The production efficiency and product quality from the identified TGE optimization strategy was further demonstrated through application to two other antibodies. The expression level of SGE (stable gene expression) can also be improved effectively with this optimization strategy. In conclusion, vector optimization via combination of optimized signal peptide, codon, and UTR is an alternative approach for efficient antibody production with high fidelity N-terminal sequence in CHO cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
- Author
-
Zhang, Xiao, Wei, Minxi, Sun, Guang, Wang, Xin, Li, Min, Lin, Zhijie, Li, Zhongyi, Li, Yufang, Fang, Mujin, Zhang, Jun, Li, Shaowei, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
HEPATITIS E , *VIRUS-like particles , *ULTRACENTRIFUGATION , *THERMAL stability , *TRANSMISSION electron microscopy , *ANTIGENS , *VACCINATION , *HEPATITIS E vaccines - Abstract
The first prophylactic vaccine against hepatitis E virus (HEV), Hecolin®, was licensed in China. Recombinant p239 virus-like particle (VLP) is its active component with dimeric protein as the basic building block harboring the immuno dominant and neutralizing epitopes. The real time and real condition stability of the prefilled syringes for the vaccine was demonstrated using both in vivo mouse potency and in vitro antigenicity assays. A total of 12 lots of Hecolin® were assessed with a set of assays after storage at 2–8 °C for 24 months. The particle characteristics of p239 VLP recovered from the aluminum-containing adjuvant was assessed with different methods including analytical ultracentrifugation, high performance size exclusion chromatography and transmission electron microscopy. The thermal and conformational stability of the adsorbed antigen was assessed using differential scanning calorimetry. The protein integrity of the recovered p239 antigen was demonstrated using SDS-PAGE with silvering staining, LC-MS and MALDI-TOF MS. Most importantly, the binding activity to the neutralizing antibody or vaccine antigenicity was measured using an epitope-specific and real-time SPR assay and a monoclonal antibody-based sandwich ELISA. Taken together, the overall good stability of the Hecolin® prefilled syringes was demonstrated with unaltered molecular and functional attributes after storage at 2–8 °C for 24 months. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
38. Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay.
- Author
-
Liu, Jian, Chen, Chunye, Zhu, Rui, Ye, Xiangzhong, Jia, Jizong, Yang, Lianwei, Wang, Yongmei, Wang, Wei, Ye, Jianghui, Li, Yimin, Zhu, Hua, Zhao, Qinjian, Zhang, Jun, Cheng, Tong, and Xia, Ningshao
- Subjects
- *
VARICELLA-zoster virus , *ENZYME-linked immunosorbent assay , *VACCINATION , *HERD immunity , *ANTIGENS , *GLYCOPROTEINS - Abstract
Varicella is a highly contagious disease caused by primary infection of Varicella zoster virus (VZV). Varicella can be severe or even lethal in susceptible adults, immunocompromised patients and neonates. Determination of the status of immunity to VZV is recommended for these high-risk populations. Furthermore, measurement of population immunity to VZV can help in developing proper varicella vaccination programmes. VZV glycoprotein E (gE) is an antigen that has been demonstrated to be a highly accurate indicator of VZV-specific immunity. In this study, recombinant gE (rgE) was used to establish a double antigen sandwich enzyme-linked immunosorbent assay (ELISA). The established sandwich ELISA showed high specificity and sensitivity in the detection of human sera, and it could detect VZV-specific antibodies at a concentration of 11.25 m IU/mL with a detection linearity interval of 11.25 to 360 m IU/mL ( R = 0.9985). The double gE antigen sandwich ELISA showed a sensitivity of 95.08 % and specificity of 100 % compared to the fluorescent-antibody-to-membrane-antigen (FAMA) test, and it showed a sensitivity of 100 % and a specificity of 94.74 % compared to a commercial neutralizing antibody detection kit. Thus, the established double antigen sandwich ELISA can be used as a sensitive and specific quantitative method to evaluate immunity to VZV. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA.
- Author
-
Cao, Lu, Wang, Xin, Fang, Mujin, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
VIRAL proteins , *MOLECULAR interactions , *ENZYME-linked immunosorbent assay , *MOLECULAR conformation , *IMMUNOGLOBULINS , *HEPATITIS E virus - Abstract
Assay artifacts were reported in plate-based immuoassays during the assessment of specific molecular interactions owing to the surface induced aggregation/conformational changes. To circumvent surface adsorption and associated artifacts, we used a solution competition ELISA by allowing unrestricted interaction between binding partners to occur in solution for better discrimination between epitopes with subtle differences. A difference of two orders of magnitude in binding to neutralizing antibodies for two truncated versions of the hepatitis E virus capsid protein was observed, while other assays showed comparable antigenicity with the same monoclonal antibodies. Discrimination of epitopes with high degree resemblance in analogous viral capsid proteins was demonstrated quantitatively based on their specific interactions. Therefore, the solution competition ELISA is a method of choice when the detection of subtle differences of two highly analogous proteins is desired. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants.
- Author
-
Li, Min, Wang, Xin, Cao, Lu, Lin, Zhijie, Wei, Minxi, Fang, Mujin, Li, Shaowei, Zhang, Jun, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
PAPILLOMAVIRUSES , *EPITOPES , *CAPSIDS , *VIRAL proteins , *AQUEOUS solutions , *VIRUS-like particles , *IMMUNOLOGICAL adjuvants - Abstract
Human papillomavirus (HPV) 6 is a human pathogen which causes genital warts. Recombinant virus-like particle (VLP) based antigens are the active components in prophylactic vaccines to elicit functional antibodies. The binding and functional characteristics of a panel of 15 murine monoclonal antibodies (mAbs) against HPV6 was quantitatively assessed. Elite conformational indicators, recognizing the conformational epitopes, are also elite viral neutralizers as demonstrated with their viral neutralization efficiency (5 mAbs with neutralization titer below 4 ng/mL) in a pseudovirion (PsV)-based system. The functionality of a given mAb is closely related to the nature of the corresponding epitope, rather than the apparent binding affinity to antigen. The epitope-specific antigenicity assays can be used to assess the binding activity of PsV or VLP preparations to neutralizing mAbs. These mAb-based assays can be used for process monitoring and for product release and characterization to confirm the existence of functional epitopes in purified antigen preparations. Due to the particulate nature of the alum adjuvants, the vaccine antigen adsorbed on adjuvants was considered largely as “a black box” due to the difficulty in analysis and visualization. Here, a novel method with fluorescence-based high content imaging for visualization and quantitating the immunoreactivity of adjuvant-adsorbed VLPs with neutralizing mAbs was developed, in which antigen desorption was not needed. The facile and quantitative in situ antigenicity analysis was amendable for automation. The integrity of a given epitope or two non-overlapping epitopes on the recombinant VLPs in their adjuvanted form can be assessed in a quantitative manner for cross-lot or cross-product comparative analysis with minimal manipulation of samples. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction.
- Author
-
Li, Zhihai, Yan, Xiaodong, Yu, Hai, Wang, Daning, Song, Shuo, Li, Yunbing, He, Maozhou, Hong, Qiyang, Zheng, Qingbing, Zhao, Qinjian, Gu, Ying, Zhang, Jun, Janssen, Mandy E.W., Cardone, Giovanni, Olson, Norman H., Baker, Timothy S., Li, Shaowei, and Xia, Ningshao
- Subjects
- *
CERVICAL cancer , *CANCER in women , *PAPILLOMAVIRUSES , *CAPSIDS , *VIRAL proteins , *HOST-virus relationships , *DISEASE prevalence - Abstract
Summary Cervical cancer is the second most prevalent malignant tumor among women worldwide. High-risk human papillomaviruses (HPVs) are believed to be the major causative pathogens of mucosal epithelial cancers including cervical cancer. The HPV capsid is made up of 360 copies of major (L1) and 72 copies of minor (L2) capsid proteins. To date, limited high-resolution structural information about the HPV capsid has hindered attempts to understand details concerning the mechanisms by which HPV assembles and infects cells. In this study, we have constructed a pseudo-atomic model of the HPV59 L1-only capsid and demonstrate that the C-terminal arm of L1 participates in virus-host interactions. Moreover, when conjugated to a scaffold protein, keyhole limpet hemocyanin (KLH), this arm is immunogenic in vivo. These results provide new insights that will help elucidate HPV biology, and hence pave a way for the design of next-generation HPV vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Modulation of host CD59 expression by varicella-zoster virus in human xenografts in vivo.
- Author
-
Wang, Wei, Wang, Xin, Yang, Lianwei, Fu, Wenkun, Pan, Dequan, Liu, Jian, Ye, Jianghui, Zhao, Qinjian, Zhu, Hua, Cheng, Tong, and Xia, Ningshao
- Subjects
- *
CD59 antigen , *VARICELLA-zoster virus , *XENOGRAFTS , *IMMUNOREGULATION , *COMPLEMENT activation , *DORSAL root ganglia , *LABORATORY mice - Abstract
Varicella-zoster virus (VZV) is the causative agent of both chickenpox (varicella) and shingles (zoster). VZV survives host defenses, even with an intact immune system, and disseminates in the host before causing disease. To date, several diverse immunomodulatory strategies used by VZV to undermine host immunity have been identified; however, few studies have addressed the complement evasion strategies used by this virus. Here, we show that expression of CD59, which is a key member of host regulators of complement activation (RCA), is significantly upregulated in response to VZV infection in human T cells and dorsal root ganglia (DRG) but not in human skin xenografts in SCID-hu mice in vivo . This is the first report demonstrating that VZV infection upregulates host CD59 expression in a tissue-specific manner in vivo , which may aid VZV in complement evasion and pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice.
- Author
-
Zhu, Rui, Liu, Jian, Chen, Chunye, Ye, Xiangzhong, Xu, Longfa, Wang, Wei, Zhao, Qinjian, Zhu, Hua, Cheng, Tong, and Xia, Ningshao
- Subjects
- *
VARICELLA-zoster virus diseases , *VARICELLA-zoster virus , *EPITOPES , *IMMUNOFLUORESCENCE , *ENZYME-linked immunosorbent assay , *LABORATORY mice , *VACCINATION - Abstract
Varicella-zoster virus (VZV) is a highly infectious agent of varicella and herpes zoster (HZ). Vaccination is by far the most effective way to prevent these diseases. More safe, stable and efficient vaccines, such as epitope-based vaccines, now have been increasingly investigated by many researchers. However, only a few VZV neutralizing epitopes have been identified to date. We have previously identified a linear epitope between amino acid residues 121 and 135 of gE. In this study, we validated that this epitope is highly conserved amongst different VZV strains that covered five existing phylogenetic clades with an identity of 100%. We evaluated the immunogenicity of the recombinant hepatitis B virus core (HBc) virus-like particles (VLPs) which included amino acids (121–135). VZV-gE-specific antibodies were detected in immunized mouse serum using ELISA. The anti-peptide antiserum positively detected VZV via Western blot and immunofluorescent staining assays. More importantly, these peptides could neutralize VZV, indicating that these peptides represented neutralizing epitopes. These findings have important implications for the development of epitope-based protective VZV vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine.
- Author
-
Liu, Jian, Zhu, Rui, Ye, Xiangzhong, Yang, Lianwei, Wang, Yongmei, Huang, Yanying, Wu, Jun, Wang, Wei, Ye, Jianghui, Li, Yimin, Zhao, Qinjian, Zhu, Hua, Cheng, Tong, and Xia, Ningshao
- Subjects
- *
MONOCLONAL antibodies , *VARICELLA-zoster virus , *GLYCOPROTEINS , *VIRAL vaccines , *HERPES zoster , *LABORATORY mice , *ENZYME-linked immunosorbent assay - Abstract
Varicella-zoster virus (VZV) is a highly infectious agent that causes varicella and herpes zoster (HZ), which may be associated with severe neuralgia. Vaccination is the most effective way to reduce the burden of the diseases. VZV glycoprotein E (gE) is the major and most immunogenic membrane protein that plays important roles in vaccine efficacy. A quantitative assay for gE content is desirable for the VZV vaccine process monitoring and product analysis. In this study, 70 monoclonal antibodies (mAbs) were obtained after immunizing mice with purified recombinant gE (rgE). The collection of mAbs was well-characterized, and a pair of high-affinity neutralization antibodies (capture mAb 4A2 and detection mAb 4H10) was selected to establish a specific and sensitive sandwich enzyme-linked immunosorbent assay (ELISA) to quantify the native and recombinant gE. The detection limit of this assay was found to be 1.95 ng/mL. Furthermore, a reasonably good correlation between the gE content (as measured by the mAb-based quantitative ELISA) and the virus titer (as measured by the 'gold standard' plaque assay) was observed when both assays were performed for tracking the kinetics of virus growth during cell culture. A total of 16 batches of lyophilized VZV vaccine were tested using the newly developed quantitative ELISA and classical plaque assay, demonstrating reasonably good correlation between gE content and virus titer. Therefore, this mAb-based gE quantitative assay serves as a rapid, stable, and sensitive method for monitoring viral antigen content, one additional quantitative method for VZV vaccine process and product characterization. This quantitative ELISA may also serve as a complementary method for virus titering. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
45. Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity.
- Author
-
Li, Tingdong, Lin, Haijun, Yu, Linqi, Xue, Miaoge, Ge, Shengxiang, Zhao, Qinjian, Zhang, Jun, and Xia, Ningshao
- Subjects
- *
ENZYME-linked immunosorbent assay , *ROTAVIRUS diseases , *MONOCLONAL antibodies , *ANTIBODY titer , *HORSERADISH peroxidase , *EPITOPES - Abstract
Conventional rotavirus infectivity assays are time consuming, labor intensive, and with low sample throughput. To overcome these problems, a 96-well microplate enzyme-linked immunospot assay (Elispot) was developed for the measurement of rotavirus infectious titers. The infected MA104 cells were stained with a horseradish peroxidase-conjugated anti-VP6 monoclonal antibody followed by detection with an ELISPOT analyzer. A linear relationship was found between spot number and input of rotavirus dose in SA11 and 10 rotavirus isolates of different genotypes. The propagation of rotavirus SA11 in MA104 cells was monitored, and the neutralizing activity of serum samples and monoclonal antibodies was determined. The 50% neutralizing titer (NT 50 ) of serum and 50% inhibitory concentration (IC 50 ) of monoclonal antibodies were correlated well with the results determined by ELISA-based neutralization assay. In conclusion, a rapid and semi-automated procedure to determine rotavirus infectivity was developed, which will be useful to study the infectivity and the neutralizing epitopes of rotavirus. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody against Lethal Enterovirus 71 Infection in a Mouse Model.
- Author
-
Li, Zhiqun, Xu, Longfa, He, Delei, Yang, Lisheng, Liu, Che, Chen, Yixin, Shih, James Wai Kuo, Zhang, Jun, Zhao, Qinjian, Cheng, Tong, and Xia, Ningshao
- Subjects
- *
ENTEROVIRUSES , *VIRUS diseases , *NEUROLOGICAL disorders , *NEUROPHARMACOLOGY , *MONOCLONAL antibodies - Abstract
Enterovirus 71 (EV71) is a neurotropic virus capable of inducing severe neurological symptoms and death. No direct targeting antivirals are useful in the treatment of severe EV71 infection. Because of low toxicity and good specificity, monoclonal antibodies (MAb) are a potential candidate for the treatment of viral infections. Therefore, we developed an EV71-specific conformational MAb with high in vitro cross-neutralization activity to heterologous EV71 subgenotypes. The in vivo treatment experiment at different days post-infection indicated that a single treatment of MAb CT11F9 within day 3 post-infection fully protected mice from morbidity and mortality (0% PBS vs. 100% at 10 µg/g per body weight ***P<0.0001). Immunohistochemical and histological analysis confirmed that CT11F9 significantly prohibited EV71 VP1 expression in various tissues and prevented EV71-induced myonecrosis. Moreover, thrice-treatment at day 4, 5, 6 post-infection was associated with an increased survival rate (18.2% single vs. 50% thrice at 20 µg/g per body weight), and the mice recovered from limb paralysis. Competitive ELISA also confirmed that CT11F9-recognized epitopes were immunodominant in humans. In conclusion, MAb CT11F9 is an ideal candidate to be humanized and used in severe EV71 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®.
- Author
-
Zhang, Xiao, Wei, Minxi, Pan, Huirong, Lin, Zhijie, Wang, Kaihang, Weng, Zusen, Zhu, Yibin, Xin, Lu, Zhang, Jun, Li, Shaowei, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
HEPATITIS E virus , *VIRUS-like particles , *RECOMBINANT microorganisms , *RECOMBINANT proteins , *CAPSIDS , *VIRAL proteins - Abstract
Highlights: [•] Recombinant capsid protein of hepatitis E virus as vaccine antigen. [•] Multiple epitope characterization using monoclonal antibodies. [•] Successful scale up and robust manufacturing of vaccine antigen. [•] Product consistency demonstrated with orthogonal analytical methods. [•] In-depth characterization of recombinant virus-like particles. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
48. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.
- Author
-
Wei, Minxi, Zhang, Xiao, Yu, Hai, Tang, Zi-Min, Wang, Kaihang, Li, Zhongyi, Zheng, Zizheng, Li, Shaowei, Zhang, Jun, Xia, Ningshao, and Zhao, Qinjian
- Subjects
- *
HEPATITIS E virus , *CAPSIDS , *VIRION , *EPITOPES , *GENE expression , *ESCHERICHIA coli - Abstract
Abstract: The protein encoded by ORF2 in hepatitis E virus (HEV) is the only capsid protein for this single-stranded RNA virus. It was previously shown that 148 aa (aa 459–606) was needed for dimer formation, whereas 239 aa (aa 368–606) was necessary to form virus-like particles (VLPs). The self-assembled VLPs of p239 were characterized with a series of methods including high performance size-exclusion chromatography to demonstrate the particulate nature of purified and properly refolded p239. A neutralizing and protective mouse monoclonal antibody (mAb) 8C11 was previously shown to bind three discontinuous peptide segments in the dimer. In addition to the good binding activity to recombinant dimeric form, E2s or E2, and VLP form p239, we demonstrated that 8C11 was able to capture the authentic HEV virions. The capability of virus capturing was demonstrated with a titration curve from 105 to 107 HEV genome copies, making binding activity to 8C11 a surrogate marker of virion-like epitopes on recombinant VLPs as well as vaccine efficacy in eliciting protective and neutralizing antibodies. Taken together, it was demonstrated that Escherichia coli expressed pORF2 proteins, p239 in particular, maintain the virion-like epitopes on VLP surface. This is consistent with the fact that p239 was demonstrated to be an effective prophylactic vaccine (recently licensed as Hecolin® in China) against HEV-induced hepatitis in a large scale clinical trial. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
49. Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay.
- Author
-
Chen, Lihong, Liu, Jian, Wang, Wei, Ye, Jianghui, Wen, Lanling, Zhao, Qinjian, Zhu, Hua, Cheng, Tong, and Xia, Ningshao
- Subjects
- *
VARICELLA-zoster virus , *GLYCOPROTEINS , *ENZYME-linked immunosorbent assay , *IMMUNOGLOBULINS , *PREDICATE calculus , *COMPARATIVE studies , *PLAQUE assay technique - Abstract
Highlights: [•] Similar to the ELISPOT method, we developed a VZV neutralization enzyme-linked immunosorbent spot (N-ELISPOT) system. [•] We applied it to quantify virus, optimizing the test antibody dilution. [•] Compared with the plaque assay, the VZV N-ELISPOT was accurate and reliable for the detection of neutralizing serum samples. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
- Author
-
Li, Tingdong, Lin, Haijun, Zhang, Yue, Li, Min, Wang, Daning, Che, Yaojian, Zhu, Yinbin, Li, Shaowei, Zhang, Jun, Ge, Shengxiang, Zhao, Qinjian, and Xia, Ningshao
- Subjects
- *
RECOMBINANT viruses , *ROTAVIRUSES , *VIRUS-like particles , *DRUG efficacy , *ESCHERICHIA coli , *MOLECULAR self-assembly , *VIRION - Abstract
Highlights: [•] Self-assembly of recombinant rotavirus virus-like particles. [•] Post-purification assembly yields homogeneous particle. [•] Virion-like epitopes on virus-like particles by on antibody binding analysis. [•] Improved stability, antigenicity and protective efficacy of double-layered VP2/6 VLPs. [•] Resemblance of Escherichia coli-derived VLPs to virus-derived double-layered particles. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.